uniQure Announces Update on U.S. Phase I/II Clinical Trial
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline...
Source: globenewswire.com
Mt 130 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mt 130. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mt 130 Today - Breaking & Trending Today
uniQure Announces Second Quarter 2022 Financial Results and
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at...
Source: globenewswire.com
uniQure Announces Update on Low-Dose Cohort in Phase I/II
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean...
Source: globenewswire.com